VIDEO: ‘Interesting’ studies on treatments for pigmented villonodular synovitis
Click Here to Manage Email Alerts
In this Healio interview, Sandra D’Angelo, MD, discussed two “interesting” studies for pigmented villonodular synovitis, or PVNS, presented at the Connective Tissue Oncology Society Annual Meeting.
One study looked at vimseltinib (Deciphera Pharmaceuticals) in patients with tenosynovial giant cell tumor.
“This offers another potential promising option for patients with PVNS, and I look forward to seeing more data with this particular compound,” D’Angelo, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, said.
The other study looked at discontinuing and rechallenging pexidartinib (Turalio, Daiichi Sankyo) in patients with tenosynovial giant cell tumor who were previously treated with pexidartinib.
Although there were a small number of patients, “studies like this are important to be able to guide the impact of stopping treatment for a disease like PVNS,” according to D’Angelo.
References:
- Desai J, et al. Paper 28. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
- Gelderblom H, et al. Paper 27. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
Collapse
Healio Interviews
Click Here to Manage Email Alerts